Background Rituximab is a FDA-approved monoclonal antibody for adults with moderate to
severe potentially life-threatening pemphigus vulgaris. Recent studies have focused on …

Intraepithelial autoimmune blistering dermatoses are a rare group of skin disorders
characterized by disruptions of inter-keratinocyte connections within the epidermis through …

Since the beginning of the COVID-19 outbreak, attention has gradually moved from the
respiratory manifestations of the disease toward its dermatologic aspects. The need for …

There are safety concerns in the treatment of pemphigus patients with immunosuppressants,
particularly rituximab (RTX), in times of the COVID‐19 pandemic. In the beginning, the …

Pemphigus vulgaris (PV) is the most common type of pemphigus group of autoimmune skin
diseases. The treatment of PV relapse is challenging especially during the coronavirus …

Background: The management of refractory pemphigus in the pandemic conditions is
challenging. There are limited data comparing the safety of rituximab and other …

Pemphigus is a rare autoimmune disease characterised by the production of pathogenic
autoantibodies in response to different desmosome proteins. The pathophysiological …

To the Editor: We read with interest the thoughtful reply by Schultz et al to our previous
correspondence regarding treatment considerations for patients with pemphigus during the …

Rituximab (RTX), as a B cell-depleting agent, is indicated in treating several malignancies
and autoimmune diseases. The management of patients currently receiving RTX and …